Clinic
Metroplex Adventist Hospital INC
Metroplex Adventist Hospital INC was paid $10.08M by Medicaid between Jul 2018 and Dec 2024, across 90 billing codes. Its largest line is 99284, emergency room visit (serious) — 46% of everything it billed.
33Billing provider infoMETROPLEX ADVENTIST HOSPITAL INC
KILLEEN, TX 76549
KILLEEN, TX 76549
33aNPI1629089966assigned 08/11/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$10.08M
24GClaims146,558
24DCodes billed90
24AFirst – last monthJul 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#45 of 320
Median peer was paid$205K
This provider vs. median49×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 81 | $5K | |
| 2020 | 3,135 | $244K | |
| 2021 | 44,551 | $2.64M | |
| 2022 | 38,542 | $2.75M | |
| 2023 | 40,069 | $2.97M | |
| 2024incomplete | 20,180 | $1.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 46% | 14,545 | 13,628 | $4.65M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 20% | 4,960 | 4,515 | $1.97M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 22,988 | 21,844 | $1.09M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 6.1% | 6,560 | 6,070 | $612K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 3,484 | 3,382 | $162K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 5,794 | 5,282 | $159K |
| 0225U | 1.5% | 2,542 | 2,475 | $149K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 5,304 | 4,707 | $135K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 1,419 | 1,378 | $131K |
| 80053 | Comprehensive metabolic panel | 1.2% | 11,424 | 10,350 | $126K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 14,680 | 13,251 | $115K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 75 | 74 | $91K |
78 more codes
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,866 | $82K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 343 | $66K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 17 | $54K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,693 | $51K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,796 | $51K |
| 81001 | <1% | 13,057 | $40K | |
| 81025 | <1% | 3,134 | $29K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,601 | $28K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 543 | $25K |
| 84484 | <1% | 3,145 | $21K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 954 | $21K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 523 | $16K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 522 | $15K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,056 | $15K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,843 | $14K |
| 84703 | <1% | 2,154 | $13K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 134 | $13K |
| 76801 | <1% | 127 | $12K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 118 | $10K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 209 | $10K |
| 93976 | <1% | 209 | $10K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 22 | $8K |
| 84702 | <1% | 749 | $7K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 186 | $6K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 33 | $6K |
| 83690 | <1% | 1,645 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,261 | $5K |
| 86780 | <1% | 247 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,806 | $4K |
| 86703 | <1% | 190 | $4K | |
| 80074 | <1% | 54 | $3K | |
| 87529 | <1% | 74 | $3K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 57 | $3K |
| 82077 | <1% | 252 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 25 | $2K |
| 86850 | <1% | 120 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,660 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 408 | $2K |
| 86900 | <1% | 565 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 383 | $1K |
| 86901 | <1% | 564 | $1K | |
| 80179 | <1% | 108 | $1K | |
| 0002A | <1% | 68 | $1K | |
| 80143 | <1% | 94 | $1K | |
| 0001A | <1% | 82 | $1K | |
| 86762 | <1% | 52 | $990.28 | |
| 86694 | <1% | 48 | $962.24 | |
| 86787 | <1% | 55 | $938.26 | |
| 0012A | <1% | 32 | $922.04 | |
| 0011A | <1% | 30 | $890.78 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 57 | $775.30 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 91 | $679.57 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 12 | $652.61 |
| 83605 | <1% | 231 | $596.12 | |
| 82950 | <1% | 90 | $590.95 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 195 | $563.07 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 365 | $377.15 |
| 85660 | <1% | 56 | $374.66 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 382 | $319.21 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 215 | $296.94 |
| 87210 | <1% | 55 | $253.68 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 24 | $249.20 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 13 | $244.57 |
| 87481 | <1% | 45 | $235.84 | |
| 82947 | <1% | 281 | $173.28 | |
| 85027 | <1% | 92 | $169.00 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 42 | $117.39 |
| 87077 | <1% | 135 | $81.92 | |
| 83880 | <1% | 13 | $65.96 | |
| 87186 | <1% | 92 | $51.36 | |
| 85610 | <1% | 28 | $50.40 | |
| 85007 | <1% | 39 | $49.01 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 90 | $47.31 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 17 | $29.65 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 15 | $25.83 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 69 | $19.22 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | 0% | 16 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 109 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGARCIA, JANET (CFO)
| Provider | Location | Paid |
|---|---|---|
| Metroplex Adventist Hospital INC | Lampasas, TX | $1.22M |
| Eduardo Ramos MD PLLC | Las Vegas, NV | $77K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.